JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2008, 57(5):208-214

History and the present state of hypolipidaemic therapy

R. Bartas1,*, J. Kolář2
1 Lékárna Aqua, Karviná
2 Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav aplikované farmacie

History of hypolipidaemic therapy is closely connected with the development of the knowledge of atherosclerosis pathogenesis and lipid metabolism. Isolation of statins (and also their synthesis) and their subsequent implementation in practice were a decisive discovery that affected contemporary cardiology. Statins rank among the most widely utilized drugs and some of them belong to very commercially successful preparations. There are very few therapeutic groups the therapeutic contribution of which is documented so well. Several prospective drugs with different mechanisms of effect are being developed at present.

Keywords: hypolipidaemics; atherosclerosis; ischemic heart disease; statins

Received: August 11, 2008; Accepted: August 27, 2008; Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartas R, Kolář J. History and the present state of hypolipidaemic therapy. Čes. slov. farm. 2008;57(5):208-214.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pater, C.: Curr. Control. Trials Cardiovasc. Med., 2001; 2, 24-37. Go to original source... Go to PubMed...
    2. Steinberg, D.: J. Lipid Res., 2004; 45, 1583-1593. Go to original source... Go to PubMed...
    3. Steinberg, D.: J. Lipid Res., 2006; 47, 1-14. Go to original source... Go to PubMed...
    4. Steinberg, D.: J. Lipid Res., 2005; 46, 179-190. Go to original source... Go to PubMed...
    5. Steinberg, D.: J. Lipid Res., 2005; 46, 2037-2051. Go to original source... Go to PubMed...
    6. All Nobel Laureates in Medicine [on line]., [cit. 2008-05-15]. Dostupný z www: <http://nobelprize.org/nobel_prizes/medicine/laureates/index.html>
    7. Endo, A.: J. Lipid Res., 1992; 33, 1569-1582. Go to original source...
    8. Bultas, J., Karetová, D.: Pace News, 2004; 3, 1-4.
    9. Steinberg, D.: J. Lipid Res., 2006; 47, 1339-1351. Go to original source... Go to PubMed...
    10. Hlinomaz, O., Groch, L.: Interv. Akut. Kardiol., 2003; 2, 123-136.
    11. Pfizer ukončil vývoj léku na cholesterol. [on line]., [cit. 2008-04-15]. Dostupný z www: <http://www.medical-tribune.cz/aktualita/1942>
    12. Sobolová, L.: Klin. Farmakol. Farm., 2005; 19, 22-26.
    13. Češka, R., Doležal, T.: Farmakoterapie 2006; 2, 183-188.
    14. Štulc, T. Ezetimib: zklamání ze studie ENHANCE. Lékařské listy 2008; 10, 30-31.
    15. --: Farmakoterapie 2007; 4, 367.
    16. Pikto-Pietkiewicz, W., Wołkowska, K., Pasierski, T.: Pharmacological Reports 2005; 57 (Suppl.), 10-19.
    17. Scharnagl, H. et al.: Atherosclerosis 2000; 153, 69-80. Go to original source... Go to PubMed...
    18. Locker, P. K. et al.: Clinical Pharmacology & Therapeutics 1995; 57, 73-88. Go to original source... Go to PubMed...
    19. Tardif, J. et al.: JAMA, 2007; 297, 1675-1682.
    20. Bultas, J.: Farmakoterapie, 2006; 2, 151-153.
    21. UPDATE 2-US FDA tells Takeda to stop some TAK-475 trials. [on line]., [cit. 2008-04-15]. Dostupný z www: <http://www.reuters.com/article/governmentFilingsNews/idUST17428120071029>
    22. Češka, R.: Kap Kardiol., 2006; 8, 22-25.
    23. Bultas, J.: Interní medicína pro praxi, 2006; 7/8, 314-322.
    24. Berger, A., Jones J. H. P., Abumweis, S., S.: Lipids Health Dis., 2004; 3, 1-19. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.